Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.

@article{Kerr2010NonclinicalSA,
  title={Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.},
  author={Janet S Kerr and Sheila Galloway and Armando A Lagrutta and Michael G. Armstrong and Thomas Miller and Victoria M. Richon and Paul A. Andrews},
  journal={International journal of toxicology},
  year={2010},
  volume={29 1},
  pages={3-19}
}
Vorinostat (SAHA, Zolinza), a histone deacetylase inhibitor, is assessed in nonclinical studies to support its approval for cutaneous T-cell lymphoma. Vorinostat is weakly mutagenic in the Ames assay; is clastogenic in rodent (ie, CHO) cells but not in normal human lymphocytes; and is weakly positive in an in vivo mouse micronucleus assay. No effects are observed on potassium ion currents in the hERG assay up to 300 microM (safety margin approximately 300-fold the approximately 1 microM serum… CONTINUE READING